Target Patient Population: Hypertension patients who are on an SGLT2 or will benefit from the addition of an SGLT2.

Study Overview: Will determine whether baxdrostat/ dapagliflozin is superior to dapagliflozin alone to slow CKD progression, assessed as the effect on change in eGFR

Study Timeline: Anticipated patient participation is 28 Months, 15 visits to the clinic

Number of Patients Currently Active in the Trial: 2

670 Glades Rd. Suite 110 Boca Raton, FL 33431P. (561) 368-0235 | F. (561) 368-0281
3863 W Broward Blvd, Fort Lauderdale, FL, USAP. (954)321-7772 | F. (954)321-5757